MORE►
precision medicine
Left: Milan Radovich, SVP and Chief Scientific Officer at Caris Life Sciences; Right: Boris L. Zaïtra, Head of Roche Corporate Business Development [Photos: LinkedIn/Roche]
North Texas’ Caris Life Sciences To Collaborate With Genentech on Novel Therapeutic Targets for Cancers
by Sandra Engelland | Dec 17, 2025
Under the terms of the agreement, Caris is eligible to receive upfront and near-term payments of $25 million and is also eligible for up to $1.1 billion of potential research, development, commercial, and net sales payments, as well as potential tiered royalties on net sales of collaboration therapies, the company said.
by Lance Murray |
May 8, 2025
Eric Matthews will provide strategic leadership to biopharma business development, and through his executive leadership, support Caris' expanding portfolio of biopharma partnerships, the company said.
MORE►
by Lance Murray |
Oct 24, 2023
Irving-based Caris said that via this multiyear agreement, Moderna will leverage Caris’ extensive library of de-identified, multimodal data solutions derived from whole exome sequencing, whole transcriptome sequencing, and protein analyses—along with claims data to improve development strategies for Moderna’s oncology pipeline.
MORE►
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Photo: Caris]
Caris Life Sciences Raises $310M to Continue Rapidly Growing in the Precision Medicine Market
by Alex Edwards | Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
by Lance Murray |
Mar 2, 2018
The new center, on the campus of UT Arlington, will be available to academic and corporate researchers. Official said it could help elevate the region as a leader in precision medicine.
MORE►
by Hubert Zajicek |
Jan 9, 2017
Artificial intelligence, emancipating role of health care consumers, and genetic testing are some of the trends to expect in 2017 Hubert Zajicek says.
MORE►
